Mizuho analyst Salim Syed lowered the firm’s price target on Cytokinetics (CYTK) to $84 from $103 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
- Cytokinetics presents additional data related to Aficamten
- Cytokinetics Announces Key Decisions at Annual Meeting
- Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology
- Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy